Late-Stage Breast Cancer Diagnosis Among Black Women in the Mid-South
MD Newsline
In this episode of MD Newsline, Dr. Janeane N. Anderson, Assistant Professor at the University of Tennessee Health Science Center and breast cancer researcher, shares insights from the ACCESS Study—an innovative qualitative research initiative focused on understanding why Black women in the Mid-South region are disproportionately diagnosed with advanced-stage breast cancer. Dr. Anderson discusses structural barriers, community-based recruitment strategies, and the importance of centering lived experiences in oncology research. She also highlights the critical need for equitable research...
info_outline
Understanding Cancer Disparities, Mistrust, and Access to Care
MD Newsline
In this episode of MD Newsline, Dr. Jordonna Brown, a medical oncologist at Kings County Hospital in New York City, shares her frontline experience caring for patients in a safety-net hospital setting. Speaking from the San Antonio Breast Cancer Symposium (SABCS), Dr. Brown discusses cancer disparities, late-stage presentation, mistrust in the healthcare system, and the evolving landscape of breast cancer treatment. She offers a candid look at the social determinants of health shaping patient outcomes—from delayed screening and misconceptions about chemotherapy to barriers in long-term...
info_outline
Inflammation and Resistance in MDS & AML: Targeting the JAK-STAT Axis
MD Newsline
In this episode of MD Newsline, Dr. Theodoros Karantanos, Assistant Professor of Medical Oncology at the Johns Hopkins University Sidney Kimmel Cancer Center, discusses the emerging role of inflammatory signaling in high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Karantanos shares insights from his laboratory research exploring how inflammatory pathways—particularly interferon gamma and JAK-STAT signaling—contribute to treatment resistance, including resistance to venetoclax. He also highlights the impact of TP53 mutations, bone marrow microenvironment...
info_outline
Host Factors in Immunotherapy: How Sex, Aging, and Lifestyle Shape Cancer Outcomes
MD Newsline
In this episode of MD Newsline, Dr. Marco Ruella, Associate Professor of Medicine at the University of Pennsylvania and Scientific Director of the Lymphoma Program, joins us from the American Society of Hematology (ASH) meeting to discuss a paradigm-shifting topic: host factors in cancer immunotherapy. Dr. Ruella explores how biological sex, aging, chronic inflammation, obesity, exercise, and the microbiome influence responses to therapies such as checkpoint inhibitors and CAR T-cell therapy. The conversation highlights emerging data, translational research, and the growing need to...
info_outline
What’s Next for CAR-T Cells? In Vivo Design, Toxicity, and Persistence
MD Newsline
In this episode of MD Newsline, Dr. Dejah Blake, a fifth-year PhD candidate at Emory University, joins us from the American Society of Hematology (ASH) conference to discuss the rapidly evolving landscape of CAR T-cell therapy. Dejah shares insights into engineering next-generation CAR T cells, improving accessibility through in vivo manufacturing, and addressing diversity gaps in clinical research. From armored CARs to gene editing and humanized mouse models, this conversation explores how innovation and equity must move forward together in advancing cancer immunotherapy. Episode...
info_outline
The Psychology of Prevention: Behavioral Strategies for Better Health Outcomes
MD Newsline
In this episode of MD Newsline, behavioral scientist Dr. Josh Klapow, registered dietitian Kim Shapira, and health advocate Sishman Rimpson explore the powerful connection between psychology, nutrition, and long-term health outcomes. Together, they unpack how behavioral patterns, mindset, and sustainable lifestyle changes influence chronic disease prevention and patient adherence. The discussion highlights the real-world challenges patients face when attempting to modify diet, physical activity, and stress management—and how healthcare professionals can better support lasting change...
info_outline
Beyond Statins: Modern Cholesterol Care, Risk Assessment, and the Future of Lipid Therapy
MD Newsline
In this episode of MD Newsline, Dr. Amber Johnson, Assistant Professor of Medicine and General Cardiologist at the University of Chicago, provides an in-depth look at modern cholesterol management and cardiovascular risk reduction. She discusses evolving lipid guidelines, aggressive LDL-C targets, statin intolerance, and the growing role of non-statin therapies. Dr. Johnson also explores emerging research on lipoprotein(a), hypertriglyceridemia, and future directions in lipid-lowering treatment. Episode Highlights Evolving Cholesterol Management and ASCVD Risk Dr. Johnson explains how...
info_outline
Man Enough to Feel: Breaking the Stigma Around Men’s Mental Health
MD Newsline
In this episode of MD Newsline, a distinguished panel of physicians, mental health leaders, former professional athletes, and performance coaches come together for a powerful discussion on men’s mental health, vulnerability, and emotional wellbeing. The conversation explores how traditional definitions of masculinity impact mental health, performance, relationships, and help-seeking behaviors—and why redefining strength is critical for future generations. Panelists include Dr. Mike Banna, Dominique Easley, Jason Sousa, Dr. Nate Evans Jr., and Dr. Pete Thomas, each bringing unique...
info_outline
Understanding Alzheimer’s Disease: Biomarkers and Early Detection
MD Newsline
In this episode of MD Newsline, Dr. Rudolph J. Castellani, a neuropathologist and Director of the Division of Neuropathology at Northwestern University, offers a deep dive into the biology, diagnosis, and ongoing controversies surrounding Alzheimer’s disease. He explores how Alzheimer’s is defined clinically and pathologically, the evolving role of biomarkers in early detection, and why modifying biomarkers has not yet translated into meaningful clinical improvement for patients. Dr. Castellani also discusses the promise and limitations of artificial intelligence, personalized medicine,...
info_outline
From Hormones to Longevity: A Modern Approach to Men’s Health
MD Newsline
In this episode of MD Newsline, a panel of men’s health experts—Dr. Tracy Gapin, Dr. Joseph Acquaye, and Justin Birckbichler—come together to discuss a modern, proactive approach to men’s health. The conversation explores the importance of prevention, hormone optimization, cardiovascular risk, and lifestyle-driven strategies to improve long-term health outcomes for men. The panel addresses common gaps in men’s healthcare, including delayed screenings, lack of awareness around hormone health, and the cultural barriers that prevent men from seeking early medical intervention. Drawing...
info_outlineDr. Litzow shares deep insights into how immunotherapy has transformed survival outcomes, how clinicians can balance efficacy and neuropsychiatric side effects, and why cross-disciplinary collaboration is key to advancing oncology care.
Episode HighlightsReal-World Evidence and Clinical Practice Dr. Litzow explains the growing importance of real-world data in validating and refining clinical trial outcomes. While clinical trials have strict eligibility criteria, real-world settings introduce more patient diversity, offering valuable insights into treatment efficacy and tolerability across broader populations.
The ECOG-ACRIN E1910 Trial and Immunotherapy Advances Dr. Litzow details the E1910 trial, which compared standard chemotherapy with and without blinatumomab, an immunotherapy agent targeting CD19 and CD3. The study demonstrated a significant survival benefit—85% versus 68%— for patients receiving blinatumomab, establishing it as a new standard of care for MRD-negative ALL patients.
Integrating MRD and Genomic Profiling in Decision-Making He highlights how MRD testing and molecular risk profiling are shaping treatment pathways, enabling clinicians to better identify patients who can potentially avoid bone marrow transplantation through effective immunotherapy.
Adapting Pediatric Regimens for Adult Patients Dr. Litzow discusses the use of pediatric-inspired chemotherapy regimens in younger adults and the challenges in adapting these treatments for older or high-risk patients. He emphasizes careful monitoring for toxicities such as hepatic and neuropsychiatric effects.
Balancing Treatment Intensity and Quality of Life With immunotherapy showing strong efficacy, Dr. Litzow anticipates future strategies that reduce chemotherapy exposure, lower toxicity, and improve patient quality of life—especially for older adults or those with comorbidities.
Future Directions: AI, Cross-Specialty Collaboration, and Inflammation Research Dr. Litzow shares his optimism about artificial intelligence enhancing trial data analysis and calls for cross-disciplinary collaboration between cancer biologists and clinicians. He also emphasizes the emerging role of inflammation in cancer development, urging broader, non-linear approaches to understanding disease mechanisms.
Key TakeawayDr. Litzow underscores a new era in ALL treatment—where immunotherapy, real-world evidence, and molecular diagnostics intersect to personalize care, extend survival, and minimize toxicity. As clinical science evolves, the focus is shifting from intensifying chemotherapy to optimizing immune-based precision therapies that improve both outcomes and quality of life.
Resources
Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Mark R. Litzow: Hera
Hosted on Acast. See acast.com/privacy for more information.